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Apparent mineralocorticoid excess (AME), a rare autosomal recessive disorder 
characterized by low renin hypertension, may display a severe or mild phenotype in patients.  
The variability in clinical presentation stems from different extents of impairment of the 11E-
hydroxysteroid dehydrogenase type 2 (HSD11B2) enzyme arising from distinct mutations in the 
encoding gene.  The computational model of the HSD11B2 protein that we constructed here will 




Mutations in 11β-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) cause an 
extraordinarily rare autosomal recessive disorder, apparent mineralocorticoid excess (AME).  
AME is a form of low renin hypertension that is potentially fatal if untreated.  Mutations in the 
HSD11B2 gene result either in severe AME or a milder phenotype (type II AME).  To date, ~40 
causative mutations have been identified.  As part of the International Consortium for Rare 
Steroid Disorders, we have diagnosed and followed the largest single worldwide cohort of 36 
AME patients.  Here, we present the genotype and clinical phenotype of these patients, 
prominently from consanguineous marriages in the Middle East, who display profound 
hypertension and hypokalemic alkalosis.  To correlate mutations with phenotypic severity, we 
constructed a computational model of the HSD11B2 protein.  Having used a similar strategy for 
the in silico evaluation of 150 mutations of CYP21A2, the disease causing gene in congenital 
adrenal hyperplasia, we now provide a full structural explanation for the clinical severity of AME 
resulting from each known HSD11B2 missense mutation.  We find that mutations that allow the 
formation of an inactive dimer, alter substrate/coenzyme binding, or impair structural stability of 
HSD11B2 yield severe AME.  In contrast, mutations that cause an indirect disruption of substrate 
binding or mildly alter intramolecular interactions result in type 2 AME.  A simple in silico 
evaluation of novel missense mutations could help predict the often-diverse phenotypes of an 




Apparent Mineralocorticoid Excess (AME) is an ultra-rare autosomal recessive disorder 
caused by a mutation in the 11E-hydroxysteroid dehydrogenase type 2 gene (HSD11B2), which 
leads to a deficiency in the HSD11B2 enzyme.  HSD11B2, a member of the short chain alcohol 
dehydrogenase family, catalyzes the NAD+-dependent dehydrogenation of cortisol.  In the 
kidney, HSD11B2 converts cortisol to inactive cortisone.  This mechanism protects the 
mineralocorticoid receptor from cortisol action, notwithstanding an equal in vitro affinity of the 
mineralocorticoid receptor for cortisol and aldosterone, and the 100- to 1000-fold higher 
circulating levels of cortisol (1, 2). 
In 1977, we described the biochemical phenotype of a patient with AME (3).  We found 
that, in the absence of HSD11B2, the mineralocorticoid receptor was occupied and stimulated 
by excess cortisol leading to hypertension without elevated aldosterone or renin levels.  AME 
patients display low birth weight, failure to thrive, low-renin hypertension, and hypokalemia.  
Defective metabolism of cortisol to cortisone leads to the pathognomonic elevation in the ratio of 
urinary tetrahydrocortisol (THF) plus allo-THF to tetrahydrocortisone (THE) 
[(THF+alloTHF)/THE]. 
In a disorder in which one of the cardinal clinical features is hypertension, insidious end 
organ damage in renal, neurological, neuromuscular, cardiovascular, and ocular systems may 
arise at an early age from chronic elevation of blood pressure or through metabolic alkalosis 
and severe hypokalemia leading to renal disease.  Cardiac failure resulting from hypokalemia, 
hypertensive crises, stroke, cardiomegaly, hypertensive retinopathy, and kidney failure are 
commonly reported complications of this disease.  All of the AME patients reported until 1998 
had the characteristic signs of severe AME.  In 1998, the first patient with a mild form of AME 
who proved to have mutations that resulted in an HSD11B2 protein with attenuated activity was 
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reported (4).  Only three clinical features of the mild AME are the same as in severe AME: low 
renin, low aldosterone, and elevated (THF+alloTHF)/THE ratio. 
Following our initial description of the disease-causing mutation in the HSD11B2 gene 
(5, 6), around 40 additional mutations have been described in less than 70 patients worldwide 
(Fig. 1A).  Despite the small number of available patients, previous studies have documented 
correlations between genotype and phenotype (7, 8).  For example, mutations that severely 
attenuate HSD11B2 activity, as assessed in vitro, cause severe disease, including early fatality, 
while mutations associated with mildly attenuated enzyme activity give rise to type 2 AME, often 
with a late-onset presentation of mild hypertension. 
We recently published evidence for genotype–phenotype concordance in 1,507 families 
with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency and 220 CAH 
patients with 11β-hydroxylase deficiency (9-11).  In both studies, we used in silico dynamic 
modeling to define structural changes that each CYP21A2 and CYP11B1 mutation induces in 
the respective enzymes, namely 21-hydroxylase and 11β-hydroxylase.  By correlating these 
changes with clinical phenotype, we defined structural derangements underpinning the clinical 
variants of CAH, namely salt-wasting, simple virilizing, and non-classical CAH (9).  A previous 
attempt with AME mutations sought to correlate structure with function using a dimeric 
quaternary structure (12).  This structure-function relationship is in contradiction with 
experimental evidence suggesting that the HSD11B2 monomer is, in fact, the active form of the 
enzyme (13). 
In this study, we provide extensive data on the demographics, genotype, phenotype, and 
hormonal profile of 36 AME patients from our International Consortium for Rare Steroid 
Disorders, together with long-term outcomes in a subset.  To evaluate genotype-structure-
phenotype correlations, we constructed a 3D homology model of HSD11B2, to which we 
mapped all the known HSD11B2 missense mutations, and additionally carried out molecular 
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dynamic simulations to understand alterations in structural flexibility.  Thus, as with CAH, we 
present our prediction of disease severity based on mutation-induced changes in HSD11B2 
structure.  This in silico strategy, we believe, will facilitate the prediction of AME phenotype when 
new mutations are discovered. 
 
RESULTS 
We report the demographics and clinical phenotype of 36 genetically confirmed AME 
patients from the International Consortium of Rare Steroid Disorders.  The majority of patients 
were of Omani (22/36) and Persian (6/36) descent, with 75% being from consanguineous 
marriages, mainly within Oman (Fig. 1B and Dataset S1).  The median age of AME diagnosis 
was 4.6 years (range: 0.1-15) and the cohort was distributed equally for either sex.  The majority 
of patients (86%) were born at term, with 76% being born small for gestational age.  Fig. 1A 
shows that, in our cohort, there were 6 missense, 1 insertion, 2 deletion, and 3 frameshift 
mutations, and 2 indels.  Expected from the pathophysiology of AME, the presenting mean 
arterial pressure was elevated above the 90th percentile for all subjects (Fig. 1C).  The average 
serum potassium level at diagnosis was low at 2.72 mmol/L (range: 1.5 to 4.1 mmol/L), while 
serum bicarbonate was high at 29.5 mmol/L (range: 20-38 mmol/L) (Figs. 1D and 1E).  Serum 
aldosterone levels were expectedly low (Fig. 1F), with two patients with elevated levels due to 
unclear reasons.  Additionally, renin levels were low, except for two patients (10.4 and 14 
ng/mL/hr) that were on therapy (Table 1).  In a subset of 29 patients, the average (THF + 
alloTHF)/THE ratio, representing the major urinary metabolites of cortisol and cortisone, was 
significantly elevated at 19 (range: 3-55, normal: 1.0) (Fig. 1G).  Of note is that 27 of 36 (75%) 
patients also presented with nephrocalcinosis.  The nephrocalcinosis may arise from chronic 
long-standing hypokalemia as noted, for example, in Bartter syndrome type III (14).  
To understand whether the clinical phenotype of HSD11B2 deficiency could be predicted 
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by examining changes in enzyme structure induced by a given HSD11B2 mutation, we 
performed in silico analytics using three estrogenic HSD17B1 [PDB id 1IOL (15), 1JTV (16), 
1FDV (17)] that exhibited a 27% sequence similarity with HSD11B2 over 284 amino acids (Fig. 
S1A).  The human HSD11B2 model exhibited a characteristic conserved NAD-binding Rossman 
Fold motif (Fig. S1B) with an adjacent substrate-binding site (Fig. S1C and S1D).  500 ns of 
molecular dynamics (MD) simulations of the monomer and dimeric forms of HSD11B2 indicated 
a stable model with stably folded protein (Figs. S1E to S1H).  We used ICM software to 
determine ΔΔG of missense mutations found in AME patients or experimentally engineered 
mutations.  All mutations (Fig. 2A) showed an increase in ΔΔG values, suggesting the loss of 
protein stability and function (Fig. 2B). 
HSD11B2 exists as a homodimer in its inactive state (13).  Four residues, namely, R186, 
E190, A237 and R336, lie at the dimer interface and could therefore interfere with dimer 
formation (Fig. 2C).  Residues R186 and E190 are positioned at the dimer interface on the α4 
helix.  An inter-subunit ion-pair interaction (R186-E190) is formed as a result of the two-fold 
inverted symmetry of the adjacent subunit (Fig. 2D), akin to the R112-E120 ion pair in HSD17B1 
(15-17).  Importantly, this interaction was found to be stable, and was maintained throughout the 
course of 500 ns MD simulations (Figs. 2E, 2F and 2G).  Furthermore, the interaction was found 
to stabilize the α4 helix and maintains flexibility around the coenzyme-binding site.  Thus, the 
R186C mutation results in the loss of inter-subunit ion pair and pushes the equilibrium towards 
formation of an active monomeric enzyme (Fig. 2H).  It also prevents the formation of the intra-
helical ion pair interaction and thus permits the destabilization of structural elements around the 
coenzyme-binding site. 
There are several other disruptive mutations at this dimer interface involving residues 
A237, D244, L251 and D176.  The residue A237 is surrounded by L241 and V239 from both 
HSD11B2 subunits.  Its mutation to Val enhances hydrophobicity of this cluster and strengthens 
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the enzyme’s inactive dimeric state (Fig. 2I).  The residue D244 not only creates an intra-subunit 
salt bridge with R336 that holds the α5 helix and E7 sheets together, but also hydrogen bond 
interactions with R360 from the adjacent subunit (Fig. 2J).  Its mutation to Asn decreases the 
strength of the R360 interaction leading to the loss of the salt bridge with R366 – this, in turn, 
impairs protein stability.  Similarly, mutation of a hydrophobic L251 side chain to hydroxyl group 
of Ser increases polarity and forms a hydrogen bond with the positively charged side chain 
groups of R360 – this enhances dimer binding (Fig. 2K).  Finally, the mutation of D176 to Asn 
creates a hydrogen bond between asparagine and T200, thus enhancing the inactive dimer 
state (Fig. 2L). 
Mutations of HSD11B2 residues which form the substrate or coenzyme (NAD+) binding 
pocket have been shown in in vitro studies to eliminate enzyme activity (18) and cause severe 
AME.  For example, Y226 is located in the substrate-binding pocket (Fig. 3A).  The aromatic 
phenol side chain forms hydrophobic interactions with the aromatic ring of the substrate.  The 
Y226N mutation replaces this residue with a non-aromatic residue resulting in the loss of 
hydrophobic stacking, which interferes with substrate binding (Fig. 3A).  Furthermore, this 
mutation changes the side chain from being hydrophobic to hydrophilic, which is unfavorable for 
the binding of a hydrophobic substrate.  The A221V mutation replaces the short side chain with 
a slightly bulkier side chain of Val, thus interfering with substrate binding by reducing the volume 
of the pocket, while the A221G mutation decreases hydrophobicity and introduces flexibility 
around the rigid binding pocket (Fig. 3B). 
Our model shows that the polar 17-OH group in cortisol is tucked in a hydrophobic 
region surrounded by Y226, P227 and L229.  This hydroxyl group is absent in corticosterone, 
which results in enhanced hydrophobic interactions and ~10-fold higher binding affinity to 
HSD11B2 compared with cortisol (Fig S2A).  Besides the kidney, HSD11B2 is also expressed in 
the placenta.  Although the mineralocorticoid receptor is not expressed in this tissue, HSD11B2 
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inactivates cortisol to eliminate its growth-inhibiting and pro-apoptotic effects during embryonic 
development.  During pregnancy, the high level of progesterone in the maternal circulation can 
bind to and modulate HSD11B2 activity.  This may translate into effects of any loss-of-function 
mutations that disrupt progesterone binding on birth weight.  For example, the A221V mutation 
severely affects the binding of progesterone more than cortisol because of the steric clashes 
between Val and the projecting methyl groups in progesterone (Fig. S2B).  Very interestingly, we 
find that the two patients with the A221V mutations were small for gestational age (Table 1).   
Likewise, the A221G mutation affects progesterone binding indirectly by altering the structure of 
the binding site.  Similarly, the Y226N mutation is more detrimental to progesterone binding as it 
reduces hydrophobic interactions between the progesterone skeleton and the hydroxyphenyl 
ring of tyrosine (Fig. S2B).  In contrast, P227 provides indirect structural support to the binding 
site, and mutation to Leu has similar affects for both cortisol and progesterone (Fig. S2B). 
There are four mutations that reside in and disrupt the co-enzyme binding site, thus 
severely impairing HSD11B2 activity.  The side chain of residue L179 is normally positioned 
spatially in a short turn between the E4 sheet and D4 helix (Fig. 3C).  By allowing interactions 
with the hydrophobic side chains of V174 and L282, these interactions make the coenzyme-
binding site more flexible.  Mutation to Arg introduces a guanidinium side chain, which allows 
interactions with the carboxyl group side chain of E172 and the hydroxyl group side chain of 
T184 (Fig. 3C), thus introducing rigidity to the turn and decreasing the flexibility required for 
optimal enzyme function (7).  Situated in the coenzyme binding pocket, Y232 is a highly 
conserved residue in the Rossman fold motif (19), suggesting that its mutation will be 
detrimental to enzyme activity (20).  The hydroxyl-phenyl side chain of Y232 forms important 
hydrogen bonds with N171 and NAD+, holding the coenzyme in correct position for its catalytic 
function (Fig. 3D).  This interaction is disrupted in the Y232C mutation causing severe AME.  
The importance of this residue in enzyme activity has been independently confirmed by several 
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engineered mutations (20) (Fig. 3D).  In the G89D mutation, the carboxyl side chain of Asp 
displays severe steric clashes with the ribose sugar moiety of adenosine, which affects the 
binding of NAD+ (Fig. 3E).  Another engineered mutation K236R leads to the disruption of NAD 
binding (Fig. 3F).  While retaining the ability to interact with the NAD+ through hydrogen 
bonding, the mutation abolishes enzyme activity (20). 
Impairments in structural stability of HSD11B2 disrupt its tertiary structure causing a 
marked attenuation of enzyme activity and severe AME.  The residue L250 is positioned in the 
D5 helix, and its side chains sit in a tight hydrophobic pocket surrounded by the side chains of 
L204, F246, W253, V255 and V257 (Fig. 4A).  The hydrophobic pocket residues are locked by 
an ion-pair interaction between R208-E249.  Introduction of a Pro side chain breaks the D5 helix 
by introducing rigidity, which prevents a large, bulky guanidinium side chain of Arg from being 
accommodated in the tight binding pocket (Fig. 4A).  A subsequent loss of hydrophobicity in this 
region affects structural stability.  Another stable intra-helical ion pair interaction is formed 
between D144 and R147 (Fig. 4B).  This interaction allows the D3 helix to pack tightly with the 
adjacent β sheets near the NAD+ binding site.  The D144V mutation results in the loss of this 
interaction and destabilizes the packing arrangement (Fig. 4B).  The hydrophobic packing is 
also disrupted in F185S mutation, when the aromatic side chain of phenylalanine, surrounded 
by hydrophobic residues of V182, C188 and M189, is replaced with a polar side chain of serine 
(Fig. 4C).  Similarly, the hydrophobic side chain of L363, surrounded by M347, I350 and F362, is 
positioned in a helix-turn-helix (Fig. 4D).  The L363P mutation disrupts the helix and the local 
structural environment. 
Furthermore, several mutations can disrupt packing of the HSD11B2 protein to impair 
stability through the introduction of a bulkier residue.  Residue A328 forms hydrophobic 
interaction with V215, I260, I325 and Y338 (Fig. 4E).  By replacing the alanine with a bulkier Val 
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residue, the A328V mutation causes steric clashes with the side chain of I260 and Y338 from 
the surrounding E sheets (Fig. 4E).  Residue S180 is positioned on a loop and its hydroxyl group 
side chain interacts with the side chain and backbone nitrogen of T184 (Fig. 4F).  This side 
chain lies within a very constricted space and restricts the accommodation of any bulkier 
residue, which causes steric clashes, in fact, without altering the protein structure.  Thus, a Phe 
side chain with a bulky aromatic ring, as in S180F mutation, is not tolerated at this position (Fig. 
4F). 
Multiple hydrogen bonds and salt bridges between polar residues stabilize the tertiary 
structure of the HSD11B2 enzyme.  Certain mutations cause a loss of these interactions, 
resulting in inactive enzyme and severe AME.  For example, the salt bridge between R208 and 
E249 is critical (Fig. 4G).  Its loss, as in the case of the R208C and R208H mutations, 
destabilizes the protein and results in severe disease (Fig. 4G).  Likewise, D223 forms a salt 
bridge with R337 (Fig. 4H).  By replacing this salt bridge with a less strong bond, a hydrogen 
bond, the D223N mutation changes the negatively charged residue to an uncharged polar 
residue resulting in a marked attenuation of in vitro activity (21).  This also suggests that the salt 
bridge plays a crucial role in maintaining HSD11B2 stability and activity.  The side chains of 
R213 form hydrogen bonds with the backbone atoms of residues A331 and L329 (Fig. 4I).  By 
diminishes these hydrogen bonds, which help maintain the tertiary structure of the protein, 
R213C mutation impairs enzyme stability (Fig. 4I). 
The Arg/Tyr cluster from residues 335 to 339 has previously been implicated in 
maintaining protein stability, although precise mechanism has remained unclear (22).  Mutations 
involving these residues have been reported in AME patients, including the R337C and Y338H.  
Simulations of the monomer and dimeric HSD11B2 models suggest that residue R337 forms a 
salt bridge interaction with D223 and hydrogen bonds with the OH group of Y339 (Fig. 4J).  
There interactions appear to be important in maintaining correct folding and stability of the 
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protein.  Thus, its mutation to Cys abolishes both the salt bridge and hydrogen bond to 
destabilize the enzyme and cause severe AME.  Genetically engineered mutations of this 
residue further show that R337K, which maintains polarity and positive charge, reduces enzyme 
activity by 70%, while R337A, which is similar to R337C in having uncharged and short side 
chains, inactivates HSD11B2 completely (Fig. 4J) (22).  In the same Arg/Tyr cluster, mutation of 
Y338 to His inactivates the enzyme to cause severe AME.  Our model suggests that this Tyr 
residue forms hydrophobic interactions with A328 and hydrogen bonds with D327 (Fig. 4K).  
Both interactions help sustain protein stability, so that the substitution of Tyr with His, for 
example, inactivates HSD11B2.  This is because, although Y338H retains the hydrogen bonding 
ability, it has shorter side chains that destabilize the enzyme.  Similarly, the substitution of Tyr 
with Phe in an engineered Y338F construct is not tolerated.  Here, hydrophobic interactions are 
retained but hydrogen bonding is abolished (22).  Finally, R337 and Y338 in the Arg/Tyr cluster 
are also highly conserved across many species; thus, any changes to these residues are 
unlikely to be tolerated (22). 
Several mutations are reported to cause a milder form of AME with a less severe clinical 
and biochemical manifestations.  The relevant mutated constructs were shown to have 
maintained HSD11B2 activity in vitro (4, 18, 23), consistent with the less severe clinical 
phenotype.  Structurally, these mutations can either indirectly disrupt substrate binding (such as 
the P227L mutation in one of our patient) or alter protein structure (such as the R279C and 
R359W mutations) to attenuate, but not abolish enzyme activity (Fig. 5).  Notably, while the 
P227 residue does not lie in a position that directly interacts with the substrate, its adjacent 
positioning to residue Y226 suggests that it may have a role in substrate binding (Fig. 5A).  In 
fact, this residue forms the ‘kink’ in the loop region, maintaining the conformation of the active 
site and also holds Y226 in the correct position to optimally interact with the substrate.  Mutation 
of this residue to Leu (P227L) disrupts the ‘kink’ and alters the positioning of Y226 (Fig. 5A).   
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Two non-conservative mutations thought to disrupt the tertiary structure of HSD11B2 
have been identified in patients with AME type 2.  R279 forms a hydrogen bond with the 
backbone of N171, which helps maintain and stabilize the local protein environment (Fig. 5B).  
Replacement of R279 by a residue that does not form a hydrogen bond, as in the R279C 
mutation, leads to mild attenuation, but not total elimination of HSD11B2 activity (23), consistent 
with a mild clinical phenotype (Fig. 5B).  Another non-conservative mutation, R359W, changes 
the properties of the side chain from charged to hydrophobic.  This alters the local interaction 
within the protein structure, in which the positively charged side chain of R359 forms a hydrogen 
bond with the backbone carbonyl oxygen of I350 (Fig. 5C).  A loss of this interaction contributes 
towards the enhanced structural flexibility, causing attenuation of enzyme activity.  Of note is 
that both R279C and R359W cause minimal disruption to the intramolecular interactions and 
occur near the surface of the protein. 
 
DISCUSSION 
AME is an extremely rare disorder, with less than one hundred cases reported to date 
(24).  Most patients are found in populations where consanguinity and endogamy are common 
(25).  The low prevalence of AME and the relatively limited number of mutations in the 
HSD11B2 enzyme have together rendered it difficult to study genotype-phenotype associations.  
Our consortium represents the largest AME cohort described phenotypically. 
Of the 16 patients we have reported preliminarily (6, 8, 26-28), follow up data was 
available on 8 males and 6 females (6 to 26 years of age).  Like CAH, height of the patients 
improved, but fell below the target height (height SDS: -1.1 ± 0.6).  Cardiovascular 
complications were prominent, with three patients dying from cardiac arrest at 16, 16 and 17 
years of age.  Severe hypertension left ventricular hypertrophy (12/16) and hypertensive 
retinopathy (10/16) were prominent clinical features.  For the 13 surviving patients with available 
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follow-up echocardiograms, 12 had persistent left ventricular hypertrophy, 3 showed aortic root 
dilation, and 2 had aortic insufficiency.  Another notable clinical feature was nephrocalcinosis, 
which persisted in 8/9 patients at 4.1 to 14.5 years follow-up, despite treatment of hypokalemia.  
Four patients developed renal insufficiency more than 10 years after diagnosis, with two 
progressing to renal failure and received renal transplantation (29).  Interestingly, following 
transplant, these patients no longer showed clinical signs of AME, with a remission of the low-
renin hypertension and hypokalemic alkalosis when medical treatment with spironolactone was 
discontinued. 
On follow-up, three females conceived spontaneously.  One patient had 2 miscarriages 
prior to a viable pregnancy that she carried to term.  Spironolactone was discontinued due to 
non-compliance, which resulted in severe hypertension and renal failure.  The second patient 
carried her pregnancy to term, with spironolactone being discontinued in the first trimester and 
ensuing blood pressure control with methyldopa.  The third patient was treated with eplerenone 
and hydrochlorothiazide during pregnancy; she had severe hypertension (BP: 217/91) 
associated with preeclampsia at 24 weeks of gestation and delivered a nonviable fetus.  This 
long-range follow up of an ultra-rare disorder has profound implications on the future 
management of newly discovered AME patients. 
The role of the mineralocorticoid receptor and the HSD11B2 enzyme in essential 
hypertension is being increasingly recognized.  The presentation of the mild form of AME 
mimics essential hypertension as there are no electrolyte abnormalities.  Mild mutations were 
identified in patients with mild clinical markers of AME, namely, low aldosterone, hypertension, 
and abnormal ratio of cortisol to cortisone and in vitro studies demonstrated a very mild 
alteration in enzyme activity (6, 23).  The mild form is best identified by mutations in the 
HSD11B2 gene as other hallmarks, such as low birth weight, poor growth, severe hypertension 
and hypokalemia, are absent.  Increased (THF+alloTHF)/THE ratios have also been reported in 
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16 to 32% of essential hypertension, consistent with HSD11B2 dysfunction (30, 31).  
Furthermore, treatment with mineralocorticoid receptor antagonists has been shown to lower 
blood pressure in patients with essential hypertension, heart failure and hypertension resistant 
to conventional antihypertensives (32-34).  For a subset of patients with low renin-low 
aldosterone hypertension, mineralocorticoid receptor antagonists may be the most 
effective therapy.  HSD11B2 enzyme deficiency also accelerates atherogenesis and causes 
proinflammatory changes in the endothelium of mouse models; this is reduced by eplerenone 
(35).  Polymorphisms of the HSD11B2 gene have been associated with hypertension (36).   
Despite these overlaps between clinical features of mild AME and essential hypertension, the 
most definitive diagnosis of the former is by genetic diagnosis. 
One of the main factors contributing to the development of hypertension is the amount of 
salt intake.  Nevertheless, not all individuals respond to a salt load in the same way; notably, 
some develop hypertension while others do not.  AME is a form of salt-sensitive monogenic 
hypertension.  In addition to expression in the kidney, HSD11B2 is also expressed in the brain.  
Brain-specific Hsd11b2 knockout mice show increased salt appetite and salt sensitivity (37).  It 
has been suggested that minor abnormalities of this enzyme may explain salt-sensitivity in the 
pathogenesis in essential hypertension.  
Early reports suggested that changes in the structural integrity of HSD11B2 can cause 
severe AME, whereas intronic mutations that yield mildly impaired enzyme could result in type 2 
disease (38).  To this end, correlations between clinical phenotype and the magnitude of 
reduction in enzymatic activity in vitro for certain mutations have been described (7).  
Nonetheless, precise structural changes induced by specific mutations have hitherto remained 
unsolved.  A prior in silico model has used the dimeric quaternary structure, but it was later 
shown experimentally that the active form of HSD11B2 was, in fact, the monomer (12, 13).  
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Here, we report the successful identification, by computational modeling, of structural changes 
in silico that are induced by HSD11B2 mutations.  We have used this analysis to provide 
structural explanations for the effect of mutations on HSD11B2 function.  We find that mutations 
that cause severe AME are those that enhance dimerization, disrupt the substrate- or 
coenzyme-binding site, or severely impair structural stability.  We have also categorized 
mutations that result in a mild AME (type 2) phenotype, namely P227L, R279C and R359W, as 
those indirectly disrupting substrate binding or causing mild alterations in protein structure. 
Based on observations from the humanized model, we find that most of the mutations 
occur in yet uncharacterized regions of the HSD11B2 protein.  We thus employed molecular 
dynamic (MD) simulations in explicit solvent on both monomeric and dimeric models to 
understand the structural flexibility of these residues.  We conclude that HSD11B2 mutations 
exert their effect by disrupting intra-molecular interactions, which alter protein structure and 
impair structural stability.  Of these mutations, those that affect multiple salt bridge interactions, 
hydrogen bond networks and hydrophobic patches have a greater impact on disrupting overall 
structural integrity.  In contrast, mutations that only affect a single intra-molecular interaction, 
such as R279C and R359W, cause relatively minor disruptions, and are, therefore, more 
tolerated.  This is because loss of a single interaction is likely to be compensated by interactions 
formed between other residues. 
The analysis presented here is based on a given missense mutation affecting the 
HSD11B2 protein.  However, in the case of compound heterozygosity, we would expect the 
resulting clinical phenotype to result from the combined effects of two mutations.  As an 
example, a patient presenting with mild AME (type 2) was a compound heterozygote having 
inherited two HSD11B2 mutations (18).  As one of the mutations, Y232C, occurred at the 
coenzyme-binding site, we predict on basis of our in silico categorization, that it would severely 
attenuate enzymatic activity.  However, the other mutation, L376P (residues beyond residue 
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369), is expected to result in HSD11B2 with sufficient residual activity.  The resulting mild clinical 
phenotype is therefore consistent with only 50% of near-normal functioning enzyme.  In yet 
another example, despite inheriting two mutations expected to result in severely attenuated 
HSD11B2, the patient did not present with AME until 21 years of age (18).  There is no ready 
explanation for this, but it is known that minimal residual enzyme activity might just be sufficient 
for mineralocorticoid escape. 
Overall, therefore, we infer that there is close concordance between the structural 
disruption of HSD11B2 caused by a given mutation and the resulting clinical phenotype.  We 
have recently performed a similar exhaustive in silico analysis for the ~150 known mutations 
affecting the steroidogenic enzyme 21-hydroxylase (9).  Almost all mutations were categorized 
in terms of specific patterns of structural changes that correlated tightly with the three known 
clinical phenotypes of congenital adrenal hyperplasia (CAH), namely salt wasting, simple 
virilizing and non-classical CAH.  For example, if the mutation was located within 5Ǻ of the 
substrate- or heme-binding site, the outcome invariably was salt-wasting CAH, whereas if non-
conserved hydrophobic patches were disrupted, the disease was a milder, simple virilizing 
variety. 
Our in silico categorization of clinical severity of mutations can potentially be used to 
predict clinical severity or phenotype of new mutations very early during gestation, particularly 
with the availability of prenatal diagnostic testing.  To this end, using patients from our CAH 
cohort, we can now establish, as early as 6 weeks of gestation, whether the fetus is affected or 
a carrier by Next Generation Sequencing of free fetal DNA in the mother’s plasma (39).  Our in 
silico prediction tool, together with this new technology, should change the paradigm for “early” 




The cohort of AME patients, which was a part of the International Consortium of Rare 
Steroid Disorders (Principal Investigator: Maria I. New), was recruited independently in 7 
countries by pediatric endocrinologists, with appropriate Institutional Review Board (IRB) or 
Ethics Committee approval.  Genotyping was performed by PCR at Mount Sinai or at overseas 
institutions using appropriate primer sets, as described previously (6, 28).  Serum potassium, 
bicarbonate and aldosterone, and urinary THF and THE levels were measured locally at 
commercial laboratories.  The methods for computational modeling, including molecular 
dynamic modeling, are found in the Supplementary Methods section and in Haider et al (9). 
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Figure 1:  Clinical Profile for Patients with Apparent Mineralocorticoid Excess (AME) Due 
to 11β-Hydroxysteroid Dehydrogenase Type 2 Deficiency from 7 Nations of the 
International Consortium for Rare Steroid Disorders.  (A) Structure of the human HSD11B2 
gene that contains 5 exons, showing known mutations and those harbored by 36 patients in this 
international cohort (bold).  (B) Worldwide distribution of our cases of 11β-hydroxysteroid 
dehydrogenase type 2 deficiency.  Mean arterial blood pressure (C), and serum potassium (D), 
bicarbonate (E) and aldosterone (F) levels in our patient cohort shown as a function of age.  
Urinary tetrahydrocortisol (THF) plus allo-THF to tetrahydrocortisone (THE) 
[(THF+alloTHF)/THE ratio] (G) is shown for each genotype.  Bold lines show the 90th percentile 
(C), or upper (E) or lower (D, F) limits of normal ranges.  Filled red and blue circles, respectively, 
represent females and males with overt AME; red open circle represents a female with AME 
type 2. 
 
Figure 2:  Disruptive Mutations Affecting the Dimer Interface of HSD11B2.  (A) Human 
HSD11B2 dimer model constructed using existing HSD17B1 crystal structures: 1IOL (co-
crystallized with 17β-estradiol) that was the most complete structure, with no missing residues; 
1JTV (1.5Å) that was co-crystallized with testosterone and exhibited higher resolution over 1IOL 
(2.3Å); and 1FDV that was co-crystallized with the coenzyme NAD.  The positions of all known 
mutated residues are indicated.  (B) ∆∆G values for severe (red) or mild (black) HSD11B2 
mutations.  (C) At the dimer interface, two R186-E190 ion pairs are formed between the two-fold 
inverted symmetry of the adjacent subunits.  In case of the monomer (D), an intra-helical ion 
pair is formed, which is similar to the R112 and E120 salt bridge formed in the HSD17B1 
templates.  (E) Spatial positions of mutations (blue) mapped on one subunit.  The two subunits 
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are distinctly colored (brown and blue).  NAD+ (yellow) and cortisol (green) are illustrated as 
sticks.  The ion pair interaction at the dimer interface is stable throughout the 500 ns simulation 
(F).  However, some fluctuation is observed in the intra-helical interaction due to conformational 
changes in the monomer (G).  (H) R186 makes ion pair interactions with E190 from adjacent 
subunit.  The R186C mutation results in the loss of the ion pair interaction.  An intra-helical ion 
pair formed between R186-E190 in the monomer is also lost.  (I) A237V mutation enhances 
hydrophobicity at the interface.  (J) D244 forms an intra-subunit ion pair interaction with R336, 
as well as hydrogen bonds with R360 from the adjacent subunit.  The polar uncharged side 
chain of asparagine in the mutant is unable to provide structural stability.  (K) The OH group in 
the L251S mutation makes a hydrogen bond with R361 from the adjacent subunit, thus 
enhancing the interaction at the dimer interface.  (L) The hydrogen bond formed between 
D176N and T200 enhances the inactive dimer state. 
 
Figure 3:  Interference with Coenzyme or Substrate Binding to HSD11B2.  (A) The tyrosine 
at position 226 forms the wall of the substrate-binding site and imparts hydrophobicity.  A 
mutation to N226 results in loss of hydrophobic stacking rendering it unfavorable for substrate 
binding.  (B) A221V mutation reduces the volume of the substrate-binding pocket, while A221G 
increased flexibility around the binding site.  (C) In the L179R mutation, the positively charged 
guanidinium side chain makes hydrogen bonds with the size chains of T184 and E172, thereby 
reducing the flexibility around the NAD+-binding site.  (D) The hydroxy-phenyl side chain of Y232 
makes hydrogen bonds with the hydroxyl group of ribose sugar and side chain of N171.  These 
hydrogen bonds are essential, as mutations to phenylalanine, serine or cysteine are not 
tolerated.   The mutation to phenylalanine removes the hydroxyl group and leads to loss of the 
hydrogen bond, whereas mutation to serine with a shorter side chain results in increased 
distance of OH group from the NAD+, and again prevents effective hydrogen bonding – both 
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mutations result in inactive enzyme.  (E) The carboxyl side chain of aspartic acid in the G89D 
mutation causes severe steric clashes with the ribose sugar moiety of adenosine in NAD and 
affects coenzyme binding.  (F) The bulkier side chain in K236R mutation decreases the size of 
the coenzyme-binding pocket.  This is because the Arg residue with a bulkier side chain 
decreases the size of the coenzyme pocket, making it unfavorable for optimal NAD+ binding. 
 
Figure 4: Mutations Affecting HSD11B2 Stability.  (A) L250 is positioned on α5 helix and the 
side chain is surrounded in a constricted hydrophobic pocket.  A mutation to bulky arginine or 
proline that introduces helix distortion is not tolerated.  (B) The D144V mutation results in the 
loss of the D144-R147 ion pair interaction and destabilizes the D3 helix packing arrangement 
near the NAD-binding site.  (C) The polar side chain in F185S mutation disrupts the hydrophobic 
packing formed by V182, C188 and M189.  (D) The hydrophobic L363 residue is positioned in a 
helix-turn-helix, surrounded by M347, I350 and F362.  Mutation to proline disrupts the helix and 
the local structural environment.  (E) In the A328V mutant, the side chain of valine displays 
steric clashes within the hydrophobic pocket.  (F) The hydroxyl group side chain of S180 makes 
interactions with the backbone atoms and the side chain of T184.  A phenylalanine side chain 
abolishes these interactions and imparts flexibility to the loop.  (G) R208-E249 ion pair 
interactions hold D4 and D5 helices together.  R208H/C mutants are unable to form this 
interaction.  (H) The carboxyl side chain of D223 makes hydrogen bonds with the side chains of 
Q261 and R337.  Mutation to Asn disrupts the hydrogen bond with R337.  (I) The R213C 
mutation results in the loss of hydrogen bond interactions formed between the arginine side 
chain and the backbone atoms of A331 and L329.  (J) R337 makes an ion pair interaction with 
D223 and also a hydrogen bond with Y339.  While the lysine side chain retains decreased 
ability to form hydrogen bond with Y339, a mutation to histidine, cysteine, or alanine completely 
abolishes the R337-D223 ion pair interaction.  (K) The hydroxy-phenyl side chain of Y338 
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makes hydrogen bond with the backbone atoms of D327 and A328.  These interactions 
maintain the spatial positions of D7 and E7.  A mutation to histidine or phenylalanine results in 
the loss of these interactions and introduces flexibility. 
 
Figure 5:  HSD11B2 Mutations Causing Mild AME Type 2.  (A) P227 forms a ‘kink’ in the loop 
and helps to correctly position Y226 to optimally interact with the substrate.  An increase in 
flexibility of the loop in the P227L mutation results in misalignment of Y226.  (B) The hydrogen 
bond between R279 and N171 is one of many that hold E4 and E6 sheets together.  It also 
orients the side chain of N171 to interact with NAD+.  Mutation to cysteine results in the loss of 
these interactions.  (C) R359-I350 interactions maintain the helix-turn-helix. The R359W 
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Disease  Engineered  
Mutant G (kcal/mol)  Mutant 
G 
(kcal/mol)   Mutant 
G 
(kcal/mol)  Mutant 
G 
(kcal/mol) 
G89D 0.5  P227L 0.3  D91N 1.6  Y338H 1.8 
D144V 1.7  Y232C 3.8  E115G 3.3  Y338A 2.7 
D176N 2.1  A237V 0.8  E115K 2.6  Y338F 0.6 
L179R 0.5  D244N 1.1  Y232F 1.0  Y339A 3.3 
S180F 1.2  L250R 2.3  K236R 0.3  Y339H 1.8 
F185S 1.5  L250P 3.2  R335K 2.2  Y339F 0.8 
R186C 4.2  L251S 0.4  R335Q 1.6    
R208H 1.7  T267A 0.4  R335A 2.6    
R208C 4.8  R279C 4.1  R336K 1.2    
R213C 4.8  A328V 0.7  R336A 1.3    
A221V 0.4  R337C 2.8  R336Q 2.4    
A221G 1.3  Y338H 2.9  R337K 4.1    
D223N 1.0  R359W 4.0  R337A 2.8    
Y226N 2.0     R337Q 3.0    






























































































































THE Nephrocalcinosis Genotype 
524 M 40 1.9 Y US (Chippewa) Y 11.1 180 112 134.7 77.7 2.1 38 <1 0.03 26.8 N L250_L251delinsPS/L250_L251delinsPS 
1054 M 40 2.3 Y Italian N 10.5 170 95 120.0 76.3 2.6 31 <1 0.08 33.0 Y D244N/L250R 
1058 F 40 2.1 Y US (African American) N 9.0 130 90 103.3 74.7 2.7 33  0.30 8.9 Y R186C/R186C 
1061 M 40 2.3 Y US (Persian) N 5.3 140 83 102.0 69.3 2.7 30 <1 0.12 12.5 N R337_Y338delinsH/R337_Y338delinsH 
1063 F 40 2.6 N US (African American) N 4.0 142 98 112.7 66.7 2.8 31  <0.12 14.9 Y R186C/R186C 
1101 F 40 2.4 Y Iranian Y 5.5 160 100 120.0 68.3     5 0.11 6.7 N R337C/R337C 
1105 M 40 2.1 Y Iranian Y 13.7 170 110 130.0 79.7   6 0.07 6.9 N R337C/R337C 
1107 F 40 2.2 Y Iranian Y 15.0 220 160 180.0 82.3     1 7.90 8.9 N R337C/R337C 
1262 M 40 2.0 Y Omani N 11.3 175 134 147.7 77.7 2.3 38 <1 0.47 27.9 Y R208C/R208C 
1265 M 40 2.0 Y Omani N 9.3 147 94 111.7 75.0 2.2 37 <1 0.40 27.3 Y R208C/R208C 
1278 M 40 2.0 Y Australian (Persian) Y 14.2 170 115 133.3 81.3 3.5 29 <1 7.90 9.0 Y R337_Y338delinsH/R337_Y338delinsH 
1416 M 40 2.0 Y Canadian (Persian) N 8.0 130 90 103.3 74.0 2.4 38 <1 0.07 20.1 Y R337_Y338delinsH/R337_Y338delinsH 
1567 F term 3.6 N US (Mennonite) Y 12.6 160 90 113.3 78.7 4.1 26 <1 0.70 3.0 N P227L/P227L 
2500 M 40 2.5 Y Australian (Turkish) N 3.2 143 86 105.0 63.3 2.8 34 <1 0.06 13.8 Y L287Cfs*36/L287Cfs*36 
5390 F 36 2.0 N US (Pakistani) Y 11.0 225 120 155.0 77.3 2.4 33 <1 0.64 28.0 Y Y299del/Y299del 
9968 F 36 2.0 N Omani Y 0.9 150 90 110.0 57.0 3.0 28 <1 <0.15 3.8 Y R74Gfs*43/R74Gfs*43 
12629 F term 2.0 Y Omani Y 1.3 110 70 83.3 57.0 2.9 20 0.37 14.00  Y A221V/A221V 
12630 F term 2.0 Y Omani Y 1.0 115 70 85.0 57.0 3.3 25 0.37 0.20   Y A221V/A221V 
12633 M 40 1.8 Y Omani Y 1.0 156 76 102.7 55.3 2.4 30 0.37 0.20 25.5 Y V321_V322insAPV/V321_V322insAPV 
12634 F 40 2.1 Y Omani Y 0.7 138 80 99.3 57.0 3.0 28 0.37 0.20   Y V321_V322insAPV/V321_V322insAPV 
12637 M 36 1.9 Y Omani Y 0.4 150 87 108.0 55.3 3.1 26 0.25 0.20 44.0 Y R74Gfs*43/R74Gfs*43 
12640 F term 2.0 Y Omani Y 0.1 123 70 87.7 57.0 2.3 32 0.93 <0.2 5.0 Y R74Gfs*43/R74Gfs*43 
12643 M term 2.2 Y Omani Y 0.3 145 78 100.3 55.3 2.2 33 0.87 10.70  Y R74Gfs*43/R74Gfs*43 
12645 M 36 2.2 N Omani Y 1.2 155 90 111.7 55.3 2.8 29 <1   55.0 Y V321_V322insAPV/V321_V322insAPV 
12646 M term 2.0 Y Omani Y 0.8 146 80 102.0 55.3 2.1 25 0.16 0.90  Y T267A/T267A 
12649 M term 2.3 Y Omani Y 1.6 115 70 85.0 55.3 1.5 32 0.37 0.50 36.4 Y R74Gfs*43/R74Gfs*43 
12650 M term 2.2 Y Omani Y 0.3 120 70 86.7 55.3 2.7 27 0.16 0.20  N R74Gfs*43/R74Gfs*43 
12653 M term 2.2 Y Omani Y 0.7 116 79 91.3 55.3 2.8 32 <1 <0.2 5.1 Y R74Gfs*43/R74Gfs*43 
12654 M 34 1.5 N Omani Y 0.3 151 70 97.0 55.3 3.9 24 <1 0.20 12.5 Y R74Gfs*43/R74Gfs*43 
12657 F term 2.9 N Omani Y 1.0 125 74 91.0 57.0 2.6 31 <1 <0.2 31.8 Y T267A/T267A 
12659 F term 2.3 Y Omani Y 1.8 120 77 91.3 57.0 2.9 30 <1 <0.2 12.2 Y E115_L116del/E115_L116del 
12662 F term 1.9 Y Omani Y 5.0 140 58 85.3 68.3 3.1 25 0.37 0.20   Y T267A/T267A 
12663 F term 2.9 N Omani Y 1.0 120 80 93.3 57.0 2.8 27 0.37  6.1 N T267A/T267A 
12664 F term 2.6 N Omani Y 4.0 135 87 103.0 66.7 2.9 25 <1   27.0 Y T267A/T267A 
12665 F term 2.3 Y Omani Y 4.0 184 108 133.3 66.7 2.2 24 <1 <0.2 5.9 Y T267A/T267A 
12803 F 40 1.8 Y US (American Indian) N 3.0 140 90 106.7 64.0 2.3 30 <1 0.14 32.1 N E356Vfs*40/E356Vfs*40 




The amino acid sequence for human HSD11B2 was obtained from UniProt (accession 
no. P80365) and used to search for homologous proteins in the Protein Data Bank.  The top 
searches identified three estrogenic 17β-hydroxysteroid dehydrogenase-1 (HSD17B1) 
templates [PDB id 1IOL, 1JTV, 1FDV (15-17)].  Multiple sequence alignment was carried out 
using ClustalX (37).  Models were constructed using the Internal Coordinate Mechanics method 
implemented in the Molsoft ICM software (38).  The spatial position of coenzyme and ligand 
were retained in their respective binding sites.  This was based on the assumption that the 
ligands and coenzyme interact in the similar manner and replicate all conserved interactions 
from the template into the model.  Several rounds of energy minimization yielded a final low-
energy conformation with no steric clashes between side chains.  The final model, which 
accounts for residues 81-369, was chosen based on a low Cα rmsd overlap between the 
HSD17B1 templates and the humanized model (0.11Å, 0.15Å, 0.21Å with 1IOL, 1JTV and 1FDV 
respectively).  Stereo chemical properties were evaluated using PROCHECK version 3.5.4 (39). 
HSD11B2 is a member of the short-chain dehydrogenase/reductase protein family, which 
exhibit highly conserved coenzyme and ligand binding domains.  High conservation in the 
overall fold between HSD17B1 and HSD11B2 permitted the adoption of structural features of 
the template into the model.  The 1FDV structure has been crystallized with NAD P+ P coenzyme.  A 
large ligand-binding pocket located adjacent to the coenzyme-binding site accommodates 
estradiol (1IOL) and testosterone (1JTV) in two different orientations.  The natural substrate of 
HSD11B2, cortisol, was docked in the ligand-binding pocket using the docking suite of the ICM 
software (38). 
Models were initially generated as monomers.  Dimers were created after 
superimposition of the monomers on the two-fold inverted-symmetry related half of the 
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monomer in the 1IOL template.  Monomeric and the dimeric forms of HSD11B2 were subjected 
to restraint-free atomistic molecular dynamics simulations for 500ns each to (a) test the stability 
of the models and (b) understand the structural role of mutations at the dimer interface.  AMBER 
ff99SB-ILDN force field was used to describe the systems (40).  The force field parameters for 
NAD were obtained from the AMBER parameter database (41).  The coordinates for cortisol 
were sketched and minimized in the ICM software (38) and parameterized using the 
Antechamber program (42).  The systems were solvated using TIP3P water molecules in a box 
of size 75 x 69 x 81 ÅP3P (monomer) and 104 x 69 x 81 Å P3P (dimer), whose boundaries extended at 
least 10Å from the edge of the solute.  Counter ions were added to neutralize the charges.  
Equilibration was carried out in two phases employing 10ns each of isothermal-isochoric (NVT) 
ensemble using a Langevin thermostat set at 300K and isothermal-isobaric (NPT) ensemble 
using a Berendsen barostat set at 1atm, hydrogen mass portioning and a time step of 4 fs.  The 
final production run was carried out till 500ns.  ACEMD (43) was the preferred choice of MD 
engine, running on NVIDIA GTX780 GPUs.  All analysis was carried out using the AMBER suite 
of programs (44). 
Molecular graphics images were generated using the ICM browser (38).  A list of 
currently known missense mutations, their corresponding clinical features and enzyme activity 
were extracted and cross-evaluated from various original publications. 
 
LEGENDS TO SUPPLEMENTARY FIGURES 
Figure S1: The Human HSD11B2 Model.  (A) Sequence alignment between the human 
HSD17B1 templates (PDB id 1FDV, 1IOL, 1JTV) and HSD11B2 sequence.  Conserved 
residues are highlighted green, and partial conservation within the same amino acid 
family is highlighted in yellow.  The sequence similarity between the templates and 
HSD11B2 sequence is 27%.  (B) HSD11B2 coenzyme-binding site.  NAD+ (yellow sticks) 
is surrounded by 20 amino acids and includes T88, G89, D91, S92, F94, V113, L114, 
M137, D138, L139, T140, N167, V191, N192, V217, S219, Y232, K236, F265 and F267.  
(C) Docking of cortisol to the HSD11B2 model.  The substrate-binding site (blue mesh) 
lies adjacent to the NAD+-binding site (yellow sticks).  The volume of the cavity is 412 Å3, 
as identified by the pocket finder program in the ICM suite.  (D) HSD11B2 substrate-
binding site.  Cortisol (green sticks) is surrounded by 14 residues and includes N171, 
S219, Y226, C228, L229, Y232, C264, F307, S310, L311, L344, Q364, F367 and I368.  
RMSD plots of CD atoms in monomer (E) and individual monomers in the dimeric (F) 
models over 500 ns molecular dynamic (MD) simulation run, as well as radius of gyration 
(Rg) plots of the monomer (G) and individual monomers in the dimeric (H) models.  
These plots highlight the structural stability of HSD11B2. 
 
Figure S2:  Interaction of HSD11B2 with Corticosterone and Progesterone.  (A) 
During the simulations, the 17-OH group in cortisol (green) is tucked in a hydrophobic 
region surrounded by the aromatic ring of Y226, P227, and the side chains of L229.  This 
polar 17-OH group is not present in corticosterone (cream) and might contribute to 
enhanced hydrophobic interactions around this hydrophobic region.  (B) A221V/G 
mutation lie in the vicinity of the 19-methyl group of progesterone.  Additionally, Y226N 
and P227L mutations are also likely to influence the differential binding of progesterone 
(purple) and cortisol (green).  This is due to the slight changes in the structure of 
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